FrancophonIA/ELRC3.0 huggingface dataset:
English: The medicine can only be obtained with a prescription.
Estonian: Cancidas on retseptiravim.
English: • Macrogol/PEG-4000
Estonian: • Makrogool/PEG-4000
English: The active substance ibuprofen shows an environmental risk for the aquatic environment especially to fish.
Estonian: Toimeaine ibuprofeen on keskkonnas ohtlik veekeskkonnale, eelkõige kaladele.
English: Do not take for more than 3 days.
Estonian: Mitte võtta kauem kui 3 päeva.
English: Section 5.1 Pharmacodynamic properties
Estonian: Lõik 5.1 Farmakodünaamilised omadused
English: • are under 18 years Talk to a pharmacist or your doctor before taking if you:
Estonian: • olete alla 18 aasta vanune Enne ravimi võtmist pidage nõu oma apteekri või arstiga, kui te:
English: The exact mechanism of action of ibuprofen is thought to be through peripheral inhibition of cyclooxygenases and subsequent prostaglandin synthesise inhibition.
Estonian: Ibuprofeeni täpne toimemehhanism arvatakse seisnevat tsüklooksügenaaside perifeerses inhibeerimises ja sellele järgnevas prostaglandiini sünteesi inhibeerimises.
English: The product information may be subsequently updated by the Member State competent authorities, in liaison with the Reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC.
Estonian: Liikmesriikide pädevad ametiasutused võivad vajaduse korral referentliikmesriigiga konsulteerides selles ravimiteabes edaspidi muudatusi teha, järgides direktiivi 2001/83/EÜ III jaotise 4. peatükis kehtestatud korda.
English: Amendments to the relevant sections of the product information
Estonian: Muudatused, mis tuleb teha ravimiteabe asjakohastesse lõikudesse
English: [The following wording should be amended as follows] If your symptoms do not get better after 3 days, if they get worse or if you get new symptoms, talk to your doctor.
Estonian: Kui pärast 3 päeva möödumist teie sümptomid ei parane, kui need halvenevad või tekib uusi sümptomeid, pidage nõu oma arstiga.
English: Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Estonian: C. PAKENDI INFOLEHT Enne ravimi kasutamist lugege hoolikalt infolehte, sest siin on teile vajalikku teavet.
English: Children under18 years: [The following wording should be amended as follows] This product is not recommended forDo not give to children under 18 years.
Estonian: Alla 18 aasta vanused lapsed: [Järgmist teksti tuleb muuta järgmiselt] See ravim ei ole soovitatavMitte anda alla 18-aastastele lastele.
English: [The following wording should be amended as follows] This medicinal product should not be taken with other medicinal products containing paracetamol, ibuprofen, acetylsalicylic acid, salicylates or with any other anti-inflammatory drugs (NSAIDs) unless under a doctor's instruction.
Estonian: Seda ravimit ei tohi võtta koos teiste paratsetamooli, ibuprofeeni, atsetüülsalitsüülhapet või salitsülaate sisaldavate ravimitega ega teiste põletikuvastaste ravimitega (mittesteroidsed põletikuvastased ravimid), välja arvatud arsti ettekirjutusel.
English: What {Paracetamol/Ibuprofen 500 mg/150mg film coated tablets}{Novogesic 500 mg/150 mg film coated tablets}contain macrogol/PEG 4000
Estonian: Mida {Paracetamol/Ibuprofen 500 mg / 150 mg õhukese polümeerikattega tabletid}{Novogesic 500 mg / 150 mg õhukese polümeerikattega tabletid} sisaldab makrogool/PEG 4000
English: How to take {Paracetamol/Ibuprofen 500 mg/150mg film coated tablets}{Novogesic 500 mg/150 mg film coated tablets}
Estonian: Kuidas {Paracetamol/Ibuprofen 500 mg / 150 mg õhukese polümeerikattega tablette}{Novogesic 500 mg / 150 mg õhukese polümeerikattega tablette} võtta
English: [The following phrase is deleted as it was duplication]
Estonian: [Järgmine lause kustutatakse, sest see kordus]
English: [The following AEs are described as follows:] ‘Paraesthesia' to frequency Rare (moved from Very Rare) ‘Oedema' to frequency Common (moved from Very Rare)
Estonian: [Järgmisi kõrvaltoimeid kirjeldatakse järgmiselt:] ‘Paresteesia' esinemissageduseks harv (varem 'väga harv') ‘Ödeemi' esinemissageduseks sage (varem 'väga harv')
English: The valid product information is the final version achieved during the Coordination group procedure with the following amendments (insertion, replacement or deletion of the text as appropriate) to reflect the agreed wording as provided below:
Estonian: Kehtiv ravimiteave on koordineerimisrühma menetluse tulemusena saavutatud lõplik versioon kokkulepitud sõnastuse kajastamiseks järgmiste alltoodud muudatustega (vastavalt vajadusele sisestatav, asendatav või kustutatav tekst):
English: Section 4.4 Special warnings and precautions for use [The wording below should be inserted in this section]
Estonian: Lõik 4.4 Erihoiatused ja ettevaatusabinõud kasutamisel [Sellesse lõiku tuleb lisada järgmine tekst]
English: B. Labelling Carton
Estonian: B. Pakendi märgistus Karp
English: This medicine is for short term use and is not recommended for use beyond 3 days.
Estonian: See ravim on ette nähtud lühiajaliseks kasutamiseks ning seda ei ole soovitatav kasutada kauem kui 3 päeva.
English: Section 6.1 List of excipients [The following phrase is amended]
Estonian: Lõik 6.1 Abiainete loetelu [Järgmist lauset muudetakse]
English: For short term use only (not more than 3 days).
Estonian: Ainult lühiajaliseks kasutamiseks (mitte kauem kui 3 päeva).
English: Treatment should be stopped in those patients who develop severe liver failure (see section 4.3).
Estonian: Raske maksapuudulikkuse tekkimisel tuleb patsientidel ravi lõpetada (vt lõik 4.3).
English: Adults: [The wording below should be inserted in this section] Do not take for more than 3 days.
Estonian: Täiskasvanud: [Sellesse lõiku tuleb lisada järgmine tekst] Mitte võtta kauem kui 3 päeva.
English: [The wording below should be inserted in this section] Treatment should be stopped in those patients who develop severe renal failure (see section 4.3).
Estonian: [Sellesse lõiku tuleb lisada järgmine tekst] Raske neerupuudulikkuse tekkimisel tuleb patsientidel ravi lõpetada (vt lõik 4.3).
English: Do not take if you: [The wording below should be inserted in this section]
Estonian: Ärge võtke, kui te: [Sellesse lõiku tuleb sisestada järgmine tekst]
English: [The wording below should be inserted in this section] - You should not take this product for longer than 3 days.
Estonian: [Sellesse lõiku tuleb lisada järgmine tekst] - Ärge võtke seda ravimit kauem kui 3 päeva.
English: Hepatic Impairment
Estonian: Suukaudseks kasutamiseks.
English: [The phrase below should be amended as follows]
Estonian: [Järgmist teksti tuleb muuta järgmiselt]
English: For oral administration and short term use only (not more than 3 days).
Estonian: Suukaudseks manustamiseks ja ainult lühiajaliseks kasutamiseks (mitte rohkem kui 3 päeva).
English: Dose reduction is recommended in patients showing signs of worsening hepatic function.
Estonian: Süveneva maksakahjustuse nähtude tekkimisel on patsientidel soovitatav annust vähendada.
English: Renal Impairment
Estonian: Neerukahjustus
English: Ibuprofen [The following phrase is deleted]
Estonian: Lõik 5.3 Prekliinilised ohutusandmed Ibuprofeen [Järgmine lause kustutatakse]
English: C. Package Leaflet
Estonian: Maksakahjustus
English: The vaccine contains a mineral oil.
Estonian: Vaktsiin sisaldab mineraalõli.
English: If you need more information about how this product may be used, you should consult your national veterinary authority.
Estonian: Kui soovite rohkem teavet selle kohta, kuidas seda ravimit võib kasutada, pöörduge palun oma riigi veterinaarameti poole.
English: This differentiation is important for disease surveillance and control.
Estonian: See eristamisvõimalus on oluline haiguse seire ja tõrje seisukohast.
English: In common with many adjuvanted vaccines swelling may occur at the vaccination site which may last for about 14 days.
Estonian: Sarnaselt mitme adjuvantvaktsiiniga võib vaktsineerimiskohal tekkida turse, mis võib püsida umbes 14 päeva.
English: The vaccine will only be used as part of an approved national disease control programme.
Estonian: Vaktsiini võib kasutada üksnes osana riiklikult heaks kiidetud haiguse leviku tõkestamise programmi raames.
English: Due to the current epidemiological situation of avian influenza and the consequent threat to both human and animal health, the Committee recommended the granting of a Marketing Authorisation.
Estonian: Seoses linnugripi praeguse epidemioloogilise olukorraga ja sellest tuleneva ohuga nii inimeste kui loomade tervisele soovitas komitee anda sellele vaktsiinile müügiluba.
English: This means that it has yet not been possible to obtain complete information about the product.
Estonian: See tähendab, et ammendavat teavet selle vaktsiini kohta pole seni olnud võimalik hankida.
English: The European Medicines Agency (EMEA) will review additional information that will become available according to an agreed timetable and this summary will be updated as necessary.
Estonian: Euroopa Ravimiamet (EMEA) vaatab edaspidi vastavalt kehtestatud ajakavale läbi kõik täiendavad kättesaadavaks saanud andmed ning vajadusel uuendab käesolevat kokkuvõtet.
English: The vaccine does not contain any ingredients that are likely to pose a risk for consumers of vaccinated birds.
Estonian: Vaktsiin ei sisalda niisuguseid koostisaineid, mis võiksid ohustada vaktsineeritud lindude toiduks tarbijaid.
English: • The results of the safety studies indicated that the product is safe for chickens and ducks.
Estonian: • Ohutusuuringute tulemused näitasid, et see vaktsiin on kanadele ja partidele ohutu.
English: The person who injects the vaccine should be careful to avoid accidental self injection.
Estonian: Vaktsiini süstiv inimene peab hoolikalt jälgima, et ta kogemata ennast süstlaga ei torkaks.
English: This is because control of avian influenza is the responsibility of national veterinary authorities in consultation with the European Commission.
Estonian: See tuleneb asjaolust, et linnugripi leviku tõkestamine on siseriiklike veterinaarametite ülesanne, kes teevad seda kooskõlastatult Euroopa Komisjoniga.
English: In the future, if the birds are exposed to the avian flu virus, the immune system will be able to make those antibodies quicker and this will help them fight the disease.
Estonian: Kui lind puutub edaspidi kokku linnugripiviirusega, suudab tema immuunsüsteem toota neid antikehasid kiiremini ja see aitab tal haigusega võidelda.
English: This means that vaccinated birds make antibodies against these two antigens.
Estonian: See tähendab, et vaktsineeritud lindudel tekivad nende kahe antigeeni suhtes antikehad.
English: The vaccine was assessed in the context of an emergency situation which means that further studies with Nobilis H7N1 are still ongoing and will be assessed.
Estonian: Vaktsiini hinnati hädaolukorra tingimustes, mis tähendab, et täiendavad uuringud Nobilis H7N1-ga on alles pooleli ja nende tulemusi hinnatakse hiljem.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Nobilis Influenza H7N1 to Intervet International BV on 14/05/2007.
Estonian: Euroopa Komisjon väljastas Nobilis Influenza H7N1 müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Intervet International BV 14/05/2007.
English: • The vaccine is able to induce antibodies in a wide range of birds.
Estonian: • Vaktsiin suudab esile kutsuda antikehade tekke väga mitmesugustel lindudel.
English: The vaccine is injected intramuscularly (into a muscle) or subcutaneously (under the skin).
Estonian: Vaktsiini süstitakse intramuskulaarselt (lihasesse) või subkutaanselt (naha alla).
English: The Committee for Medicinal Products for Veterinary use concluded that the vaccine has been shown to be effective in reducing clinical disease in poultry and could be a useful tool in controlling an outbreak of avian influenza infection.
Estonian: Veterinaarravimite komitee jõudis järeldusele, et vaktsiini efektiivsus kodulindude kliinilise haigestumise vähendamisel on tõestatud ning et see võib olla linnugripi nakkuspuhangu tõrjel kasulikuks vahendiks.
English: Nobilis Influenza H7N1 is a vaccine containing an inactivated avian influenza virus H7N1 (inactivated means that the virus has been killed so that it can no longer cause the disease).
Estonian: Nobilis Influenza H7N1 on inaktiveeritud linnugripiviirust H7N1 sisaldav vaktsiin („inaktiveeritud“ tähendab, et viirus on hävitatud, nii et see ei saa enam haigust tekitada).
English: The virus used for the vaccine carries the H7 (haemagglutinin 7) and N1 (neuramidase 1) antigens.
Estonian: Vaktsiinis kasutatav viirus kannab H7 (hemaglutiniin-7) ja N1 (neuramidaas-1) antigeeni.
English: This strain has been chosen because it protects birds against virulent H7 field strains (cross-protection), while allowing differentiation of vaccinated from infected birds.
Estonian: See tüvi on valitud sellepärast, et see kaitseb linde virulentsete looduses esineda võivate H7-tüvede vastu (ristkaitse), võimaldades eristada vaktsineeritud linde nakatunud lindudest.
English: • If the circulating avian influenza field virus has a different N component to the N1 included in the vaccine, it may be possible to differentiate between vaccinated from infected birds by using a diagnostic test to detect Neuraminidase antibodies.
Estonian: • Kui looduses levival linnugripiviirusel on muu N-komponent kui viiruses sisalduv N1, saab eristada vaktsineeritud linde nakatunud lindudest diagnostilise analüüsiga, mille käigus tuvastatakse neuraminidaasi antikehad.
English: When compared, the subcutaneous and intramuscular routes were shown to produce the same responses.
Estonian: Subkutaanse ja intramuskulaarse manustamisviisi võrdlemine näitas, et need annavad ühesuguse ravivastuse.
English: Vaccinated birds can be differentiated identified from infected birds by a diagnostic test for antibodies against the N1 component.
Estonian: Vaktsineeritud linde saab eristada nakatunud lindudest N1-komponendi vastaste antikehade diagnostilise analüüsiga.
English: The vaccine reduces the signs of flu in chickens and the excretion (shedding) and transmission (spreading) of the virus by the infected chickens and ducks.
Estonian: Vaktsiin vähendab gripinähte kanadel ning viiruse eritamist (mahajätmist) ja edasikandmist (levitamist) nakatunud kanade või partide poolt.
English: When it is given to chickens and ducks, the birds' immune system (their natural defence mechanism) makes antibodies (a special type of protein) to fight the disease.
Estonian: Selle manustamisel kanadele ja partidele toodab linnu immuunsüsteem (looduslik kaitsemehhanism) viirusega võitlemiseks antikehi (teatavat liiki valku).
English: Nobilis Influenza H7N1 is a vaccine used in chickens and ducks to protect against avian influenza.
Estonian: Nobilis Influenza H7N1 on vaktsiin, mida kasutatakse kanade ja partide kaitsmiseks linnugripi eest.
English: The benefit-risk balance may be found in module 6 of this EPAR.
Estonian: Vaktsiini kasulikkuse ja riski suhte leiate käesoleva Euroopa avaliku hindamisaruande 6. jaotisest.
English: • The vaccine has been shown reduce virus shedding in infected ducks.
Estonian: • On tõestatud, et vaktsiin vähendab viiruse väljakandumist nakatunud partidelt.
English: This vaccine has some of the same ingredients but a different antigen (virus) to Nobilis Influenza H7N1.
Estonian: Mõned selle vaktsiini koostisained olid samad, kuid see sisaldas võrreldes Nobilis Influenza H7N1-ga erinevat antigeeni (viirust).
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NOBILIS INFLUENZA H7N1
Estonian: EUROOPA AVALIK HINDAMISARUANNE NOBILIS INFLUENZA H7N1 Kokkuvõte üldsusele
English: This summary was last updated in May 2007.
Estonian: Kokkuvõtte viimane uuendus: 05/2007
English: The company also performed a laboratory study in chickens with a vaccine similar to Nobilis Influenza H7N1.
Estonian: Samuti teostas ettevõte ühe laboriuuringu kanadel Nobilis Influenza H7N1-ga sarnase vaktsiiniga.
English: • The vaccine has been shown to reduce clinical signs and mortality and reduce virus shedding in infected chickens.
Estonian: • On tõestatud, et vaktsiin vähendab nakatunud kanadel kliinilisi nähte ja suremust ning vähendab viiruse väljakandumist.
English: The company carried out laboratory studies using Nobilis Influenza H7N1 in chickens and ducks.
Estonian: Ettevõte viis läbi laboratoorsed uuringud, kasutades Nobilis Influenza H7N1 vaktsiini kanadel ja partidel.
English: Nobilis Influenza H7N1 is a vaccine.
Estonian: Nobilis Influenza H7N1 on vaktsiin.
English: Other information about Nobilis Influenza H7N1:
Estonian: Muu teave Nobilis Influenza H7N1 kohta
English: What is the risk associated with Nobilis Influenza H7N1?
Estonian: Millised on Nobilis Influenza H7N1-ga kaasnevad riskid?
English: What is Nobilis Influenza H7N1?
Estonian: Mis on Nobilis Influenza H7N1?
English: Why has Nobilis Influenza H7N1 been approved?
Estonian: Miks Nobilis Influenza H7N1 heaks kiideti?
English: How has Nobilis Influenza H7N1 been studied?
Estonian: Kuidas Nobilis Influenza H7N1 uuriti?
English: Nobilis Influenza H7N1 has been authorised under “Exceptional Circumstances”.
Estonian: Nobilis Influenza H7N1-le anti müügiluba erandkorras.
English: How does Nobilis Influenza H7N1 work?
Estonian: Kuidas Nobilis Influenza H7N1 toimib?
English: What is Nobilis Influenza H7N1 used for?
Estonian: Milleks Nobilis Influenza H7N1 kasutatakse?
English: What benefit has Nobilis Influenza H7N1 shown during the studies?
Estonian: Milles seisneb uuringute põhjal Nobilis Influenza H7N1 kasulikkus?
English: Belgium Teva Pharma B.V. Computerweg 10
Estonian: Prantsusmaa Teva Pharma B.V.
English: Pharmaceutical form Route of administration
Estonian: Ravimvorm
English: Each pack also contains:
Estonian: Iga pakend sisaldab veel:
English: Do not freeze.
Estonian: Mitte hoida lasta külmuda.
English: Date of first authorisation: 16 July 2001 Date of last renewal: 16 July 2006
Estonian: Müügiloa esmase väljastamise kuupäev: 16. juuli 2001 Müügiloa viimase uuendamise kuupäev: 16. juuli 2006
English: CEPROTIN with food and drink
Estonian: CEPROTIN koos toidu ja joogiga
English: However, this has not been observed in the clinical studies to date.
Estonian: Seni ei ole seda kliinilistes uuringutes täheldatud.
English: Nevertheless, please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Estonian: Palun informeerige siiski oma arsti, kui te kasutate või olete hiljuti kasutanud mingeid muid ravimeid, kaasa arvatud ilma retseptita ostetud ravimeid.
English: Other medicines and CEPROTIN
Estonian: Muud ravimid ja CEPROTIN
English: The individual incremental recovery ranged from 0.50 to 1.76 [(IU/dL)/(IU/kg)].
Estonian: Individuaalne inkrementaalne taastumine kõikus 0,50 kuni 1,76 [(RÜ/dl)/(RÜ/kg)].
English: CIOMS frequency categories: Very Common (>=10%); Common (>=1%<10%),Uncommon (>=0.1% - <1%), Rare (>=0.01% - <0.1%), Very Rare (<0.01%).
Estonian: CIOMS sageduskategooriad: väga sage (>=10%); sage (>=1% - <10%), aeg-ajalt (>=0,1% - <1%), harv (>=0,01% - <0,1%), väga harv (<0,01%).
English: Important information about some of the ingredients of CEPROTIN
Estonian: Oluline teave mõningate CEPROTIN'i koostisainete suhtes
English: The individual half-lives varied from 4.4 to 15.8 hours using a compartmental model and from 4.9 to 14.7 using the non-compartmental method.
Estonian: Individuaalne poolväärtusaeg varieerus 4,4 kuni 15,8 tunni vahel, kui kasutati kambri mudelit, ning 4,9 kuni 14,7 tunni vahel mittekambrilise meetodi kasutamisel.
English: Do not stop using CEPROTIN without consulting your doctor.
Estonian: Ärge lõpetage CEPROTIN'i kasutamist ilma arstiga konsulteerimata.
English: Tel.: +800 66838470
Estonian: A-1221 Vienna, Austria Tel.: +800 66838470
English: Pharmacotherapeutic group: group antithrombotic; ATC Code: B01AD12
Estonian: Farmakoterapeutiline rühm: antitrombootilised ained, ATC-kood: B01AD12
English: Patients should be advised to immediately contact their physician if these symptoms occur (see section 4.4).
Estonian: Patsientidel tuleb soovitada selliste nähtude ilmnemisel koheselt arsti poole pöörduda (vt lõik 4.4).
English: However, several small retrospective and prospective studies investigating other clinical application areas have been published in this population.
Estonian: Siiski on selle populatsiooni kohta avaldatud mitmeid väikesemahulisi retrospektiivseid ja prospektiivseid uuringuid, mis käsitlesid teisi kliinilisi kasutusalasid.
English: APC has also been shown to have profibrinolytic effects.
Estonian: APC-l on samuti tuvastatud profibrinolüütilised toimed.
English: The frequency of these ADRs is not known.
Estonian: Nende kõrvaltoimete esinemissagedus on teadmata.
English: If such a reaction occurs, your doctor will decide on the most appropriate treatment.
Estonian: Kui ilmneb antud reaktsioon, otsustab teie raviarst, milline ravi on teile kõige sobilikum.
English: Store in a refrigerator (2C - 8C).
Estonian: Hoida külmkapis (2 C.8 C).
English: If you have APC resistance which is a thromboembolic risk factor present in up to 5 % of the population in Europe your doctor may need to adjust your treatment accordingly.
Estonian: Kui teil esineb APC resistentsus, mis on veresoonte ummistumise riskifaktor kuni 5%-l Euroopa elanikkonnast, võib teie arst kohandada ravi vastavalt situatsioonile.
English: • when coumarin therapy alone is not sufficient
Estonian: • Kui kumariinravi üksi ei ole küllaldane
English: Your doctor will decide if CEPROTIN may be used during pregnancy and lactation.
Estonian: Teie arst otsustab, kas te võite raseduse või imetamise ajal CEPROTIN'i kasutada.
English: Repeated toxicity studies were not conducted because prior experience with coagulation preparations had shown them to be of limited value.
Estonian: Korduva annuse toksilisuse uuringuid ei ole läbi viidud, kuna eelnev kogemus hüübivusfaktoritega on näidanud selle piiratud väärtust.
English: If you have kidney and/or liver disease, please inform your doctor, because he may have to adjust your treatment accordingly.
Estonian: Kui teil esineb neeru ja/või maksahaigus, palun informeerige sellest oma arsti, kuna ta võib pidada vajalikuks teie ravi korrigeerimist.
English: The reports suggest that CEPROTIN is well tolerated in children and small infants.
Estonian: Tulemuste kohaselt on CEPROTIN lastel ja imikutel hästi talutav.
English: Each pack also contains one transfer needle and one filter needle.
Estonian: Iga pakend sisaldab ühte ülekandenõela ja ühte filternõela.
English: CEPROTIN belongs to a class of medicines called antithrombotics.
Estonian: CEPROTIN kuulub ravimite rühma, mida nimetatakse antitrombootilisteks aineteks.
English: Keep the vial in the outer carton in order to protect from light.
Estonian: Hoida viaal välispakendis, et kaitsta valguse eest.
English: The patients differed significantly in age, body weight and plasma volume.
Estonian: Patsiendid erinesid teineteisest oluliselt kehakaalu, vanuse ja plasmamahu poolest.
English: Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Estonian: Enne ravimi kasutamist lugege hoolikalt seda infolehte, sest siin on teile vajalikku teavet.
English: What CEPROTIN contains
Estonian: Mida CEPROTIN sisaldab
English: All unused solution, empty vials and used needles and syringes must be discarded appropriately.
Estonian: Kasutamata lahus, tühjad viaalid ning kasutatud nõelad ja süstlad nõuetekohaselt hävitada.
English: Your physician will take several blood drawings over time to determine how long protein C is remaining in your body.
Estonian: Teie arst teeb teile aeg-ajalt erinevaid vereanalüüse, et määrata, kui kaua püsib proteiin C teie organismis.
English: Patients with HIT should avoid the use of heparin containing drugs in the future.
Estonian: Patsiendid, kellel on esinenud HIT, peavad edaspidi vältima hepariini sisaldavaid preparaate.
English: In case of acute thrombosis CEPROTIN may be administered to you every 6 hours.
Estonian: Ägeda trombootilise episoodi puhul võib CEPROTIN'i manustada iga 6 tunni möödudes.